We are live on ! Find out more
OAM

Oppenheimer Asset Management Portfolio holdings

AUM $9.63B
1-Year Est. Return 30.32%
This Fund
S&P 500
This Quarter Est. Return
+7.72%
1 Year Est. Return
+30.32%
3 Year Est. Return
+85%
5 Year Est. Return
+99.62%
10 Year Est. Return
+601.29%
AUM
$7.02B
AUM Growth
+$570M
Cap. Flow
+$123M
Cap. Flow %
1.75%
Top 10 Hldgs %
15.06%
Holding
1,247
New
85
Increased
719
Reduced
392
Closed
47

Top Buys

Rank Stock Value
1
LBTYK icon
Liberty Global Class C
LBTYK
+$10.2M
2
VICI icon
VICI Properties
VICI
+$8.36M
3
ALL icon
Allstate
ALL
+$7.41M
4
UTHR icon
United Therapeutics
UTHR
+$6.59M
5
MMS icon
Maximus
MMS
+$5.9M

Sector Composition

Rank Sector Weight
1 Technology 20.61%
2 Healthcare 13.94%
3 Financials 13.92%
4 Consumer Discretionary 10.22%
5 Industrials 8.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GLOB icon
76
Globant
GLOB
$1.61B
$20.6M 0.29%
93,958
+4,827
+5% +$1.06M
LLY icon
77
Eli Lilly
LLY
$1.06T
$20.4M 0.29%
88,790
+4,988
+6% +$1M
DG icon
78
Dollar General
DG
$27.9B
$20.4M 0.29%
94,099
-113
-0.1% -$23.7K
CB icon
79
Chubb
CB
$135B
$20.2M 0.29%
127,352
+4,029
+3% +$668K
CVS icon
80
CVS Health
CVS
$122B
$20.1M 0.29%
241,441
+2,465
+1% +$202K
PAYC icon
81
Paycom
PAYC
$9.69B
$19.6M 0.28%
53,887
+800
+2% +$284K
TRV icon
82
Travelers Companies
TRV
$80.2B
$19.6M 0.28%
130,660
+2,201
+2% +$342K
QCOM icon
83
Qualcomm
QCOM
$176B
$19.2M 0.27%
134,233
+15,625
+13% +$2.11M
WST icon
84
West Pharmaceutical
WST
$24.9B
$18.8M 0.27%
52,339
+894
+2% +$295K
ANSS
85
DELISTED
Ansys
ANSS
$18.7M 0.27%
54,014
+657
+1% +$227K
CMCSA icon
86
Comcast
CMCSA
$90B
$18.4M 0.26%
322,066
+13,022
+4% +$728K
FISV
87
Fiserv Inc
FISV
$27.9B
$17.9M 0.25%
167,459
+5,238
+3% +$609K
TYL icon
88
Tyler Technologies
TYL
$12.8B
$17.5M 0.25%
38,619
-2,115
-5% -$899K
HON icon
89
Honeywell
HON
$78B
$17.4M 0.25%
84,270
+2,230
+3% +$471K
ABBV icon
90
AbbVie
ABBV
$435B
$17.4M 0.25%
154,280
+19,286
+14% +$2.17M
BIIB icon
91
Biogen
BIIB
$30.7B
$17.3M 0.25%
49,963
+3,626
+8% +$1.1M
IT icon
92
Gartner
IT
$11.7B
$17.2M 0.24%
70,988
-19,099
-21% -$4.18M
LKQ icon
93
LKQ Corp
LKQ
$6.29B
$17M 0.24%
345,060
-13,570
-4% -$648K
TMO icon
94
Thermo Fisher Scientific
TMO
$220B
$17M 0.24%
33,639
+244
+0.7% +$115K
IDXX icon
95
Idexx Laboratories
IDXX
$46.2B
$16.8M 0.24%
26,651
-204
-0.8% -$113K
ADI icon
96
Analog Devices
ADI
$190B
$16.7M 0.24%
97,121
+1,226
+1% +$196K
WELL icon
97
Welltower
WELL
$171B
$16.6M 0.24%
199,420
+432
+0.2% +$33.1K
IFF icon
98
International Flavors & Fragrances
IFF
$21.9B
$16.6M 0.24%
110,806
+2,762
+3% +$396K
VRSK icon
99
Verisk Analytics
VRSK
$25B
$16.5M 0.24%
94,614
+1,096
+1% +$194K
PFE icon
100
Pfizer
PFE
$153B
$16.4M 0.23%
420,053
+15,442
+4% +$601K

Similar funds

Oppenheimer Asset Management's Q2 2021 Portfolio in Review

As of Q2 2021, Oppenheimer Asset Management held 1,247 positions worth $7.02B, up 8.8% from $6.45B the previous quarter. Its ten largest holdings account for 15% of the portfolio.

Oppenheimer Asset Management's Q2 2021 filing shows 85 new, 719 increased, 392 reduced and 47 closed positions. Its largest new stake was United Therapeutics: 34,595 shares worth $6.21M. The largest sale was Affiliated Managers Group, an estimated $24.7M.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.

  • Oppenheimer Asset Management's largest Q2 2021 buy was United Therapeutics: 34,595 shares worth $6.21M.
  • Oppenheimer Asset Management added most to Liberty Global Class C in Q2 2021, an estimated $10.2M increase.
  • Oppenheimer Asset Management's biggest Q2 2021 reduction was Affiliated Managers Group, cutting an estimated $24.7M.
  • Oppenheimer Asset Management fully exited Varian Medical Systems, Inc. in Q2 2021, selling an estimated $5.92M.
  • Oppenheimer Asset Management's ten largest holdings make up 15% of its $7.02B portfolio in Q2 2021.
  • Oppenheimer Asset Management opened 85 new positions and closed 47 in Q2 2021.
  • Oppenheimer Asset Management's portfolio value rose 8.8% quarter-over-quarter to $7.02B.

Based on Oppenheimer Asset Management's 13F filing for Q2 2021, filed 3 Aug 2021.